drugset / Trial / NCT00998686

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

NCT00998686

Phase 3 Terminated 650 enrolled Phenomix Forest Laboratories · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to demonstrate the safety and tolerability of dutogliptin over 52 weeks.

Timeline

Start
2009-11
Primary completion
2011-10
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dutogliptin Small molecule 400 mg
Comparator Sitagliptin Small molecule 100 mg